Mineralys Therapeutics reported Tuesday that its drug Lorundrostat is moving toward a decision from the U.S. Food and Drug Administration in December [1].
The timing of the regulatory decision is critical for the company as it transitions from a research-focused entity to a commercial provider. A positive outcome would allow the firm to bring its lead candidate to market and begin generating revenue from the treatment.
During a virtual conference call held on Aug. 18, company executives provided updates on the development program and the firm's financial results for the second quarter of 2026 [1], [2]. The company said it is currently gearing up for a commercial launch to support the drug once approved [1].
Mineralys, which trades under the ticker MLYS, used the earnings call to outline how it is preparing its infrastructure for the upcoming transition [1]. This includes the development of commercial strategies, and the scaling of operations to handle the distribution of Lorundrostat [2].
The company has focused its recent efforts on ensuring that all regulatory requirements are met ahead of the December deadline [1]. The virtual call was held in a listen-only mode for participants, focusing on the trajectory of the drug's approval process and the company's readiness to enter the pharmaceutical market [2].
“Lorundrostat is moving toward a December FDA decision”
The upcoming FDA decision represents a binary event for Mineralys Therapeutics. If approved, the company will shift its primary operational focus toward sales and market penetration; if rejected or delayed, the firm may face significant financial pressure and a need to pivot its clinical strategy.
